https://orcid.org/0000-0002-4598-5128
References
- Dormer L , WalkerJ. Plain language summary of publication articles: helping disseminate published scientific articles to patients. Future Oncol.16(25), 1873–1874 (2020).
- Fizazi K , BlueI, NowakJT. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial. Future Oncol.17(4), 1699–1707 (2021).
- Oakin A , TinkerAV, GilbertLet al. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncol.17(29), 3781–3785 (2021).
- Bardia A , HurvitzSA, RugoHSet al. A plain language summary of the ASCENT study: sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncol.17(30), 3911–3924 (2021).
- Collyar DE , GautierLJ. The importance and value of engaging patients in cancer research. Future Oncol.17(28), 3663–3666 (2021).
- Davies-Teye BB , MedeirosM, ChauhanC, BaquetCR, MullinsCD. Pragmatic patient engagement in designing pragmatic oncology clinical trials. Future Oncol.17(28), 3691–3704 (2021).
- Young B , RobbKA. Understanding patient factors to increase uptake of cancer screening: a review. Future Oncol.17(28), 3757–3775 (2021).
- Weker RB . Through the patient lens: how to be a cancer patient. Future Oncol.17(28), 3685–3690 (2021).
- Gunn AH , SorensonC, GreenupRA. Navigating the high costs of cancer care: opportunities for patient engagement. Future Oncol.17(28), 3729–3742 (2021).
- Cheung CK , Tucker-SeeleyR, DaviesS. A call to action: antiracist patient engagement in adolescent and young adult oncology research and advocacy. Future Oncol.17(28), 3743–3756 (2021).
- Spartalis E , PlakopitisN, TheodoriMAet al. Thyroid cancer surgery during the coronavirus disease 2019 pandemic: perioperative management and oncological and anatomical considerations. Future Oncol.doi:10.2217/fon-2021-0585 (2021) ( Epub ahead of print).
- Karacin C , ErenT, ZeynelgilEet al. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncol.17(33), 4447–4456 (2021).
- Hochmair MJ . Plain language summary of the final results from the GioTag study. Future Oncol.17(25), 3285–3290 (2021).
- Hochmair MJ , MorabitoA, HaoDet al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncol.16(34), 2799–2808 (2021).
- Nazha B , YangJCH, OwonikokoTK. Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol.17(8), 965–977 (2021).
- Chung HC , BangYJ, FuchsCSet al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol.17(5), 491–501 (2021).
- Gounder M , AbdulRazak AR, GilliganAMet al. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol.17(22), 2923–2939 (2021).
- Gajra A , ZettlerME, MillerKAet al. Augmented intelligence to predict 30-day mortality in patients with cancer. Future Oncol.17(29), 3797–3807 (2021).
- Modi S . Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: plain language summary of the DESTINY-Breast01 study. Future Oncol.17(26), 3415–3423 (2021).
- Osinde G , NiyonzimaN, MulemaVet al. Increasing access to quality anticancer medicines in low- and middle-income countries: the experience of Uganda. Future Oncol.17(21), 2735–2745 (2021).